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0929-6646/Copyright ª 2015, ElsevierAbstract Background/Purpose: Intravenous thrombolysis for ischemic stroke saves societal
costs. The aim of this study was to investigate the cost burden that hospitals may shoulder.
Methods: Stroke code activations between May 2009 and April 2011 were recorded and divided
into groups based on work and duty time, as well as the period of the day or season. “Time cost
of nonclosing service” (TCNS) per stroke code activation or intravenous thrombolysis treatment
was calculated by dividing the time by the number of activations or thrombolysis treatments
during that period. Comparisons were made among groups.
Results: There were a total of 634 stroke code activations in a period of 2 years, and intrave-
nous thrombolysis was used in 132 (20.8%) of these cases. The rates of thrombolysis were not
statistically different between the groups. Overall, the average TCNS for the stroke team was
27.6 hours per code activation and 132.7 hours per thrombolysis treatment. The TCNS during
duty time was 1.38 times that during work time per stroke code activation and 1.46 times per
thrombolysis treatment. In summer, the TCNS was 1.6 times that in winter per code activation
and 2.2 times per thrombolysis treatment. During the late night hours, the TCNS was four times
that of early night hours per code activation and 9.8 times per thrombolysis treatment.
Conclusion: Our results demonstrate a large variation in the time cost of a nonclosing service
for intravenous thrombolysis. Payment based on piece-rate compensation may not be appro-
priate and requires improvement.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.have no conflicts of interest relevant to this article.
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Time cost of nonclosing thrombolysis service 911Introduction
Intravenous thrombolysis with tissue-type plasminogen
activator for acute ischemic stroke has been shown to be
effective and is recommended by stroke guidelines.1 How-
ever, the benefits of treatment are highly time dependent.2
A stroke team offering a nonclosing service, 24 hours a day
and 7 days a week, is required to implement this treatment.
Health care cost analysis has shown that quality-adjusted
life years gained, overall management costs including on-
call neurologists, immediate access to brain imaging, and
increased nursing for a short period are important issues.3,4
In the United States (US), an economically favorable cost-
ereimbursement ratio for hospitals was established after
the creation of diagnosis-related group 559. The US Centers
for Medicare and Medicaid Services pay hospitals approxi-
mately US$6000 more per case when thrombolysis is
administered.5 Because intravenous thrombolysis requires a
nonclosing service, payment on a piece-rate compensation
basis in which reimbursement is only based on the number
of patients treated may not be appropriate if the cost of
maintaining an on-call team is not included. A lack of
economic incentive for hospitals may be a reason for the
underutilization of such treatment, especially in developing
countries.6
A “time cost of nonclosing service” (TCNS) per stroke
team activation or thrombolysis treatment can be calcu-
lated by dividing the time by the number of activations or
thrombolysis treatments during that period. In this study,
we analyzed our TCNS per stroke team activation and per
intravenous thrombolysis treatment.
Methods
Changhua Christian Hospital (CCH) is a medical center in
western Taiwan, in an area with a population of w1.3
million. CCH participates in the Taiwan Stroke Registry,
which enrolls acute stroke patients within 10 days after
symptom onset.7 The Institutional Review Board at CCH
approved this study for human volunteers. Data on pre-
hospitalization status, hospitalization, discharge informa-
tion, and follow-up status were collected prospectively,
and written informed consent was obtained from each
participant.7
A standardized stroke pathway (code stroke) is used in
CCH to provide intravenous thrombolysis treatment
24 hours a day, 7 days a week for patients, with acute
ischemic stroke. Code stroke was activated at the emer-
gency department triage by senior nursing staff based on
the following: (1) the Cincinnati Prehospital Stroke Scale;
(2) onset time within 3 hours; and (3) advanced screening
with seven exclusion criteria (major surgery or significant
trauma in the past 14 days; bleeding in the gastrointestinal
tract or urinary tract in the past 21 days; myocardial
infarction in the past 3 months; significant head trauma in
the past 3 months; prior stroke within the past 3 months;
and a history of intracranial hemorrhage and severe dis-
eases such as active malignancy, severe liver or renal dis-
ease, severe heart failure, or severe dementia). On code
activation, an electronic record was generated. In-hospital
stroke case managers reviewed the treatment process andcollected data for analysis. The treatment protocol was
largely based on the National Institute of Neurological
Disorders and Stroke (NINDS) trial,8 and the criteria for
thrombolysis were based on the guidelines of the Taiwan
Stroke Society, which are similar to the NINDS criteria.9 If
the treatment criteria were met and informed consent was
obtained, the patient was immediately given 0.9 mg/kg of
tissue-type plasminogen activator intravenously, unless
discontinued by the treating neurologist. If the treatment
criteria were not fully met, the reasons for exclusion had to
be documented.
Code stroke activations between May 2009 and April
2011 were collected and analyzed statistically. The pa-
tients were grouped according to work time and duty time.
Work time was defined as 8:00e17:30 from Monday to
Friday, and 8:00e12:00 on Saturday. Other times of the
week were defined as duty time. Holidays were defined
according to the CCH official schedule and were included in
duty time.
For the analysis of daily distribution and characteristics
of code activation, the patients were grouped according to
the time of code activation into: (1) Morning group
(6:00e11:59); (2) Afternoon group (12:00e17:59); (3) Early
night group (18:00e23:59); and (4) Late night group
(24:00e5:59). For the analysis of seasonal distribution and
characteristics, the patients were classified into four
groups: (1) Spring group (MarcheMay); (2) Summer group
(JuneeAugust); (3) Fall group (SeptembereNovember); and
(4) Winter group (DecembereFebruary).
TCNS per code activation or thrombolysis treatment was
defined as the total number of hours used during a specific
length of time divided by the total number of code acti-
vations or thrombolysis treatments during that period.
TCNS per code activation and thrombolysis treatment was
calculated for each group. Comparisons were made be-
tween groups for age, sex, final diagnosis, rate of throm-
bolysis, and reasons for exclusion from thrombolysis. All
statistical analyses were performed using SPSS for Win-
dows, version 13.0 (SPSS Inc., Chicago, IL, USA). The sta-
tistical significance of intergroup differences was assessed
using the c2 test for categorical variables, and unpaired
two-tailed t tests were used to compare the continuous
variables. A p value < 0.05 was considered statistically
significant.Results
Between May 2009 and April 2011, there was a total of 634
code stroke activations. During this period, a total of 2350
patients with acute ischemic stroke or transient ischemic
attack were admitted to our hospital. The rate of intrave-
nous thrombolysis treatment for all ischemic stroke and
transient ischemic attack patients was 5.6%. Table 1 shows
the characteristics of all cases with code stroke activation
and by work and duty times. For all cases, the mean age
was 68  13 years, and there were more men (62.1%) than
women. One hundred and thirty-two (20.8%) patients
received intravenous thrombolysis treatment, and these
patients were significantly older than those who did not
receive thrombolysis treatment (71  12 years vs.
67  14 years, p Z 0.002). Eighty-five (13.4%) patients did
Table 1 Characteristics and “time cost of nonclosing service” per code stroke activation or intravenous thrombolysis treat-
ment for all cases and by work and duty time.a
Variable All Work time Duty time p
Number of code activations 634b 229 398 d
Age (y) 68  13 69  13 67  13 0.042
Male sex 394 (62.1) 143 (62.4) 245 (61.6) 0.826
Stroke,c
Thrombolysis 132 (20.8) 50 (21.8) 82 (20.6) 0.716
Exclusion reasonsd
Hemorrhagic stroke 102 (16.1) 35 (15.3) 66 (16.6) 0.670
TIA 42 (6.6) 11 (4.8) 31 (7.8) 0.150
Onset time 80 (12.6) 39 (17.0) 41 (10.3) 0.015
NIHSS score <4 81 (12.8) 29 (12.7) 52 (13.1) 0.885
Improving symptoms 35 (5.5) 14 (6.1) 21 (5.3) 0.660
Refusal 30 (4.7) 11 (4.8) 19 (4.8) 0.987
Others 47 (7.4) 16 (7.0) 30 (7.5) 0.799
Stroke mimic,e 85 (13.4) 24 (10.5) 56 (14.1) 0.195
TCNS per code stroke (h) 27.6 22.5 31.1 d
TCNS per thrombolysis (h) 132.7 103.2 150.7 d
Data are presented as n (%) or mean  SD.
NIHSSZ National Institutes of Health Stroke Scale; SDZ standard deviation; TCNSZ time cost of a nonclosing service; TIAZ transient
ischemic attack.
a Work time versus Duty time: p < 0.05 denotes statistical significance. c2 test for categorical variables and two-tailed t tests for
continuous variables were used.
b Seven cases could not be grouped owing to missing data.
c Patients with a final diagnosis of stroke.
d Reasons that patients with a final diagnosis of stroke were excluded from intravenous thrombolysis treatment.
e Patients without a final diagnosis of stroke.
Figure 1 Circadian distribution of code stroke activation and
intravenous thrombolysis treatment over a period of 2 years.
Gray bar Z code stroke activation; black bar Z intravenous
thrombolysis treatment.
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the stroke team was 27.6 hours per code stroke activation
and 132.7 hours per thrombolysis treatment. Three hundred
and ninety-eight of the code activations occurred during
duty time, and the mean age of the patients treated during
this time was younger than those treated during work time
(69  13 years vs. 67  13 years, p Z 0.042). The rate of
thrombolysis treatment was not significantly different be-
tween work and duty time (pZ 0.716). More patients were
excluded from thrombolysis owing to uncertain onset time
or delayed arrival during work time (17.0% during work time
vs. 10.3% during duty time, p Z 0.015). Other reasons for
exclusion from thrombolysis were not statistically different
between the two groups. There was no difference in the
percentage of patients without a final diagnosis of stroke
(p Z 0.195). In total, 5160 hours were spent during work
time and 12,360 hours during duty time. The TCNS during
duty time was 1.38 times higher than that during work time
per code stroke activation, and 1.46 times per thrombolysis
treatment.
Figure 1 shows the uneven circadian distribution of code
stroke activation and intravenous thrombolysis treatment.
Code stroke activation peaked at 10:00 (morning) and 21:00
(night). The results of analysis for the four periods are
shown in Table 2. The late night group had the smallest
number of patients (n Z 52) and youngest mean age
(63  12 years). There was no significant difference in the
rate of intravenous thrombolysis treatment (p Z 0.089).
The reasons for exclusion from thrombolysis did not differ
among the four groups, and there was no difference in the
percentage of patients who did not have a final diagnosis ofstroke (p Z 0.265). The number of code activations was
highest early at night (n Z 206) and lowest late at night
(n Z 52). In the late night group, the TCNS per code acti-
vation was four times higher than that in the early night
group (84.2 hours late at night vs. 21.3 hours early at night).
The TCNS per thrombolysis treatment in the late night
group was 9.8 times higher than that in the early night
group (876.0 hours vs. 89.4 hours, respectively).
Table 2 Characteristics and “time cost of nonclosing service” per code stroke activation or intravenous thrombolysis treat-
ment by circadian rhythm.a
Variable Late night Morning Afternoon Early night p
Number of code activationsb 52 170 196 206 d
Age (y) 63  12 69  13 68  13 68  14 0.036
Male sex 31 (59.6) 102 (60.0) 129 (65.8) 125 (60.8) 0.620
Stroke,c
Thrombolysis 5 (9.8) 41 (24.1) 37 (18.9) 49 (23.8) 0.089
Exclusion reasonsd
Hemorrhagic stroke 14 (26.9) 30 (17.6) 30 (15.3) 26 (12.6) 0.080
TIA 4 (7.7) 13 (7.6) 12 (6.1) 13 (6.3) 0.924
Onset time 8 (15.4) 24 (14.1) 32 (16.3) 16 (7.8) 0.060
NIHSS score <4 8 (15.4) 18 (10.6) 28 (14.3) 27 (13.1) 0.699
Improving symptoms 1 (1.9) 12 (7.1) 8 (4.1) 14 (6.8) 0.331
Refusal 1 (1.9) 6 (3.5) 11 (5.6) 12 (5.8) 0.513
Others 5 (9.8) 10 (5.9) 15 (7.7) 16 (7.8) 0.800
Stroke mimic,e 6 (11.5) 16 (9.4) 23 (11.7) 33 (16.0) 0.265
TCNS per code stroke (h) 84.2 25.8 22.3 21.3 d
TCNS per thrombolysis (h) 876.0 106.8 118.4 89.4 d
Data are presented as n (%) or mean  SD.
NIHSSZ National Institutes of Health Stroke Scale; SDZ standard deviation; TCNSZ time cost of a nonclosing service; TIAZ transient
ischemic attack.
a Comparisons were made among groups. p < 0.05 denotes statistical significance. c2 test for categorical variables and two-tailed t
test for continuous variables were used.
b Ten cases could not be grouped owing to missing data.
c Patients with a final diagnosis of stroke.
d Reasons that patients with a final diagnosis of stroke were excluded from intravenous thrombolysis treatment.
e Patients without a final diagnosis of stroke.
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activation and intravenous thrombolysis treatment. The
distribution was uneven with a peak between January and
March. The results of analysis for the four seasons are
shown in Table 3. There were no seasonal differences in
patient age, sex, rate of intravenous thrombolysis, and
percentage of patients without a stroke diagnosis. The
percentage of patients who were excluded from intrave-
nous thrombolysis because of improving symptoms was the
lowest in fall (2.7%) and highest in summer (10.6%;
p Z 0.037). The number of code activations was highest in
winter (n Z 196) and lowest in summer (n Z 123). In
summer, the TCNS per code activation was 1.6 times higher
than that in winter (35.9 hours in summer vs. 22.0 hours in
winter). The TCNS per thrombolysis treatment in summer
was 2.2 times higher than that in winter (200.7 hours in
summer vs. 91.9 hours in winter).Figure 2 Monthly distribution of code stroke activation and
intravenous thrombolysis treatment over a period of 2 years.
Gray bar Z code stroke activation; black bar Z intravenous
thrombolysis treatment.Discussion
CCH has one of the highest rates of intravenous thrombol-
ysis treatment for stroke in Taiwan.10 In total, 115 patients
were treated with intravenous thrombolysis for acute
ischemic stroke between May 2008 and December 2010,10
which is comparable to the 91 patients who were treated
at the National Taiwan University Hospital between January
2006 and July 2010.11 The safety and efficacy of treatment
are comparable to those in other Asian and Western coun-
tries.10,12 An in-hospital case management program to
improve the quality of stroke care according to clinicalguidelines was implemented in CCH in 2008.13 The CCH
Stroke Center is the first Taiwanese primary stroke program
certified by the Joint Commission International for clinical
care,14 and therefore our results might be of significance to
other hospitals. To the best of our knowledge, this is the
first study to report the time cost of intravenous throm-
bolysis treatment for acute ischemic stroke, and our find-
ings may provide a different viewpoint of the treatment.
Table 3 Characteristics and “time cost of nonclosing service” per code stroke activation or intravenous thrombolysis treat-
ment by season.a
Variable Spring Summer Fall Winter p
Number of code activationsb 162 123 150 196
Age (y) 67  14 66  13 69  13 69  13 0.215
Male sex 104 (64.2) 76 (61.8) 90 (60.0) 121 (61.7) 0.898
Stroke,c
Thrombolysis 36 (22.2) 22 (17.9) 27 (18.0) 47 (24.0) 0.435
Exclusion reasonsd
Hemorrhagic stroke 24 (14.8) 18 (14.6) 24 (16.0) 36 (18.4) 0.769
TIA 11 (6.8) 13 (10.6) 10 (6.7) 8 (4.1) 0.163
Onset time 17 (10.5) 13 (10.6) 28 (18.7) 22 (11.2) 0.093
NIHSS score <4 17 (10.5) 21 (17.1) 16 (10.7) 27 (13.8) 0.314
Improving symptoms 8 (4.9) 13 (10.6) 4 (2.7) 10 (5.1) 0.037
Refusal 8 (4.9) 7 (5.7) 9 (6.0) 6 (3.1) 0.571
Others 18 (11.1) 3 (2.4) 15 (10.0) 10 (5.1) 0.013
Stroke mimic,e 23 (14.2) 13 (10.6) 17 (11.3) 30 (15.3) 0.551
TCNS per code stroke (h) 27.3 35.9 29.1 22.0 d
TCNS per thrombolysis (h) 122.7 200.7 161.8 91.9 d
Data are presented as n (%) or mean  SD.
NIHSSZ National Institutes of Health Stroke Scale; SDZ standard deviation; TCNSZ time cost of a nonclosing service; TIAZ transient
ischemic attack.
a Comparisons were made among groups. p < 0.05 denotes statistical significance. c2 test for categorical variables and two-tailed t
test for continuous variables were used.
b Three cases could not be grouped owing to missing data.
c Patients with a final diagnosis of stroke.
d Reasons that patients with a final diagnosis of stroke were excluded from intravenous thrombolysis treatment.
e Patients without a final diagnosis of stroke.
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treatment for stroke saves societal costs, hospitals appear
to shoulder the burden of the cost if there are no specific
reimbursement arrangements.5 As cost calculations in the
currency of a country may not be applicable to another
country because of the difference in economic status, the
TCNS for a stroke team can be converted to a local currency
and therefore adjusted according to local economic con-
ditions. One important quality indicator of intravenous
thrombolysis treatment is that it can be provided in a
consistent manner at any time. Our results showed that in
our hospital there were no significant differences in the
rate of thrombolysis treatment and percentage of stroke
diagnosis among the different time groups. Similar results
were reported in a study of six emergency departments
including 1607 patients, which showed no differences in the
diagnosis of acute ischemic stroke and rate of tissue plas-
minogen activator administration between day and night
stroke codes.15 The calculations and comparisons of TCNS
among groups based on our data therefore seem to be
appropriate.
Although the number of code activations during duty
time (398) was higher than that during work time (229), the
total work time was much longer (12,360 hours) during duty
time than that during work time (5160 hours). Therefore,
the TCNS per code activation during duty time was 38%
higher than that during work time. The discrepancy was
even larger in the TCNS per thrombolysis treatment (46%),
because 20.8% of the patients with code activation received
thrombolysis. A much higher financial cost is therefore
needed to maintain an on-call team during duty timebecause of extra costs such as overtime pay. There were
also differences in the TCNS across the four seasons and
during the day that reached as high as a 4-fold difference
per code activation and 9.8-fold difference per thrombol-
ysis treatment. According to our results, reimbursement for
an intravenous thrombolysis service operating on a piece-
rate compensation basis may not be justified.
Code stroke activation for patients without a stroke
wastes resources. In a report by the Stroke Center at the
University of California in San Diego, 33 of 411 patients with
code stroke activations (8.0%) received intravenous
thrombolysis treatment.16 The rate of intravenous throm-
bolysis treatment used per code stroke activation depends
on the criteria of activation. In addition to a 3-hour time
window and the Cincinnati Prehospital Stroke Scale, we
used an advanced screening list based on treatment
criteria. More stringent criteria for code activation may
lead to a higher rate of treatment and save limited
resources.
A higher percentage of exclusion from thrombolysis
treatment because of uncertain onset time or delayed
arrival was found during work time. Wake-up stroke cannot
explain this observation, because the percentage in the
morning was not higher than that at late night or in the
afternoon. As stroke patients are often elderly, a quicker
response to stroke when the family is not at work and with
the patient may explain this finding.
There was a difference in the percentage of exclusion
from thrombolysis treatment owing to improving symptoms
among the seasons, which reached a peak in summer
(10.6%). A higher percentage of transient ischemic attack
Time cost of nonclosing thrombolysis service 915was also noted in summer (10.6%). Although a large-scale
study reported no association between weather and
stroke,17 our observations indicate that there may be dif-
ferences in cerebral ischemia between seasons. Further
studies are needed to elucidate the mechanisms underlying
these differences.
There are several limitations to this study. Because time
is a fixed factor, the TCNS will be higher than our calcula-
tions in hospitals with a lower patient volume. As this study
was from a single center, the number of patients was small.
For the same reason, patient selection bias may exist, as
some patients or their relatives may have refused to
transfer to our center from a local hospital. Age and stroke
severity may also be factors in their decision making, both
of which are among the treatment criteria for intravenous
thrombolysis treatment and may have biased our patient
population. However, because CCH has a high volume of
intravenous thrombolysis treatment for stroke, the TCNS
per code stroke activation and thrombolysis treatment
should be lower than for hospitals with a lower volume of
service such as community hospitals. The burden of a
nonclosing service for stroke thrombolysis is therefore
heavy for hospitals without sufficient resources. Our results
may provide an insight for health policy makers. Poor
physician reimbursement for acute stroke care is a possible
barrier to the use of thrombolytic therapy, and physician
reimbursement for the evaluation and treatment of acute
stroke is relatively low compared with other diagnoses in
both the US and Canada.18 In the US, diagnosis-related
group 559 was created to provide a higher reimbursement
for the care of patients with acute ischemic stroke treated
with thrombolysis.5 The surplus provided by this group is a
potential funding source for on-call stipends and weekend/
after-hours premium, in addition to piece-rate compensa-
tion for physicians.5 The changes in reimbursement policy
for stroke care in the US may provide an example for the
Bureau of National Health Insurance in Taiwan to improve
its current policy.
In conclusion, our study demonstrated a circadian and
seasonal distribution of code stroke activation and intra-
venous thrombolysis treatment. There was a large variation
in the TCNS for intravenous thrombolysis treatment. Pay-
ment based on piece-rate compensation may not be
appropriate and requires improvement.
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